Navigation Links
Amylin Pharmaceuticals Reports Third Quarter Financial Results
Date:10/20/2009

------ ------- ------ ------- Total costs and expenses 233,637 277,104 740,382 834,599 Operating loss (22,402) (58,742) (126,101) (196,981) Interest and other income, net (4,257) (5,338) (8,507) (4,789) Loss on impairment of investments - (14,943) (1,377) (14,943) ------ ------ ----- ------ Net loss $(26,659) $(79,023) $(135,985) $(216,713) ======== ======== ========= ========= Net loss per share - basic and diluted $(0.19) $(0.58) $(0.97) $(1.58) ====== ====== ====== ====== Shares used in computing net loss per share - basic and diluted 141,308 137,389 140,350 136,799

A reconciliation of reported GAAP operating loss to non-GAAP operating income (loss) excluding non-cash items and one-time items is provided in the table that follows (in thousands, unaudited):


                                       Quarter ended      Nine months ended
                                        September 30,        September 30,
                                       2009      2008      2009        2008
                                       ----      ----      ----        ----
    GAAP operating loss             $(22,402) $(58,742) $(126,101) $(196,981)

    Stock-based compensation          10,900    14,009     33,947     43,011
    Other non-cash compensation        4,392     5,531     15,719     18,847
    Depreciation and amortization      8,733     7,594     26,587     21,333
    Amortization of deferred revenue  (1,033)   (1,071)    (3,176)    (3,214)
    Restructuring                          -         -     11,376          -
                                       -----    ------     ------     ------

    Non-GAAP operating 
'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014  Decision Resources Group finds that while ... specialists are willing to prescribe Durata,s Dalvance (dalbavancin) ... as OPAT, approximately two-thirds of the respondents reported ... hospital inpatients. However, our findings indicate that nearly ... on OPAT following hospital discharge, and most are ...
(Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation (NYSE: ... directors has approved a quarterly dividend of $0.275 (27.5 cents) ... payable on August 1, 2014, to holders of record on ... CVS Caremark is dedicated to helping people on their ... in the United States . Through the ...
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: ... ended November 30, 2013, compared to sales of $2,202,000 for ... Once again, this quarter has also shown growth over the ... first quarter of this fiscal year. Markets that experienced sales ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Study of Zalutumumab in Combination, With Radiotherapy ... COPENHAGEN, June 24 Genmab A/S (OMX: GEN),announced ... zalutumumab,(HuMax-EGFr(TM)) in combination with radiotherapy for the treatment of,advanced ... maximum of 36,patients who are ineligible for platinum based ...
... New Recommendations Address Presurgery and Pediatric Dilemmas, ... evidence-based guidelines,address the prevention and management of ... related to the routine use of,preventive therapies. ... issue of CHEST,the peer-reviewed journal of the ...
Cached Medicine Technology:Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 2Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 3Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 2Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 3Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 4
(Date:7/13/2014)... treatment and variations in the quality of care are ... patients still varies widely between regions within Europe, according ... adults to date, published in The Lancet Oncology ... for most cancers of the blood has increased over ... of new targeted drugs in the early 2000s such ...
(Date:7/13/2014)... test for diagnosing type-1 diabetes could improve patient ... disease, according to the device,s inventors at the ... a paper to be published online July 13 ... nanotechnology to detect type-1 diabetes outside hospital settings. ... forms of diabetes mellitus, which are both characterized ...
(Date:7/13/2014)... Micro irrigation systems are mainly utilized for ... wells as to maintain soil quality. The application of ... a dominant revenue generator for manufacturers in future. The ... costs has led to the adoption of micro irrigation ... caused massive demand for micro irrigation systems, as they ...
(Date:7/13/2014)... MarketsandMarkets recently conducted a study on the ... rendering; Layout and Animation; Image Reconstruction]: Global Advancements, ... analyzes and studies the major market drivers, restraints, ... Europe, Middle East and Africa, Asia-Pacific and Latin ... of the 3D imaging market, providing an in-depth ...
(Date:7/13/2014)... The federal court overseeing thousands of ... against Johnson & Johnson’s Ethicon, Inc. is preparing to ... to get underway next month. According to an Amended ... Southern District of West Virginia on July 9, 2014, ... 2014 at 3:00 p.m. July selection is slated to ...
Breaking Medicine News(10 mins):Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4
... a Japanese study have given drug giant Novartis AG, ... The Lancet, the company’s blood pressure// drug Diovan was observed ... up to 40 percent. , The study titled the ... to 79, with high blood pressure, ischemic heart disease or ...
... from MetroHealth Medical Center and Case Western Reserve University ... have had previous spontaneous preterm births with 17 Alpha ... preterm birth would consequently reduce both short-term and lifetime ... The results of their study are reported in the ...
... study has showed that a particular group of its citizens; ... lion’s share of the arthritis// population, as well as its ... study, Edward Yelin, professor of medicine and health at the ... those with arthritis and other rheumatic conditions have increased to ...
... medication errors, says a new study by University of Arizona ... the journal Medical Care. ,The study was conducted ... professor Daniel C. Malone, Ph.D., who is also a member ... at the Critical Path Institute. ,Researchers reviewed data ...
... associated with depression in women, according to researchers at ... study being published in a recent issue of Preventive ... and depression in women. In addition, self-weighing daily, rather ... lower Body Mass Index (BMI) levels in women 40 ...
... Jose Gomes Temporao on Wednesday signed a decree declaring that ... generic version of Merck's// antiretroviral Efavirenz if the company does ... ,According to the decree, Efavirenz is a "public interest" ... not issue the decree "as a threat, nor to lower ...
Cached Medicine News:Health News:Novartis Drug Diovan Shows Superior Benefits 2Health News:Drug Therapy can Reduce Preterm Births and Decrease Lifetime Medical Costs 2Health News:America’s Arthritis Patients Take Sizeable Chunks Of Healthcare Econom 2Health News:Pharmacists' Workload Contributes To Errors 2Health News:Brazil Will Purchase Merck’s Antiretroviral If Price Not Lowere 2
... like all important missions, require ... you to your destination. The ... this dependability. So you can ... intervention and not have to ...
The FLEXI-CUT Directional Debulking System is Abbott Vascular's latest atherectomy catheter designed to enhance performance and ease-of-use....
Tests for protan and deutan defects. Patients must identify numbers or patterns formed in a matrix of small colored dots varying in color and intensity. Two editions available: 38 plate for detailed ...
STAT-CRIT is a rapid, one-step system for measuring hematocrit....
Medicine Products: